Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

114.20USD
19 Jan 2017
Change (% chg)

$-0.50 (-0.44%)
Prev Close
$114.70
Open
$114.68
Day's High
$114.90
Day's Low
$113.92
Volume
5,540,831
Avg. Vol
6,898,371
52-wk High
$126.07
52-wk Low
$94.28

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016
Wednesday, 18 Jan 2017 05:59pm EST 

Johnson & Johnson :Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing.  Full Article

Orthocell announces collaboration with Johnson & Johnson
Wednesday, 11 Jan 2017 07:21pm EST 

Orthocell Ltd : Orthocell announces collaboration with Johnson & Johnson Innovation . Announced a research collaboration agreement with Depuy Synthes Products, Inc., part of Johnson & Johnson family of companies .Deal for for its ortho-ati® stem cell approach for regeneration of degenerate tendons and ligaments.  Full Article

Orthocell announces collaboration with Johnson & Johnson
Wednesday, 11 Jan 2017 05:58pm EST 

Orthocell Ltd : Orthocell announces collaboration with Johnson & Johnson Innovation . Announced a research collaboration agreement with Depuy Synthes Products, Inc., part of Johnson & Johnson family of companies .Deal for for its ortho-ati® stem cell approach for regeneration of degenerate tendons and ligaments.  Full Article

Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2
Wednesday, 11 Jan 2017 08:00am EST 

General Electric Co : Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2 cGMP material, and enters into a collaboration and option agreement with Janssen Pharmaceuticals Inc . Bird Rock Bio says has received approval for initiation of a two-part phase 1 clinical trial for Namacizumab . Bird Rock Bio says entered into agreement with GE Healthcare for process development, formulation, manufacture of Namacizumab in preparation for phase 2 studies . Bird Rock Bio says phase 1 trial, process development, phase 2 preparation to be funded under collaboration, option agreement with Janssen Pharmaceuticals .Bird Rock Bio says entered collaboration, option agreement, under which Janssen Pharmaceuticals has exclusive right to acquire co after phase 1 data readout.  Full Article

Johnson & Johnson announces quarterly dividend for Q1 2017
Tuesday, 3 Jan 2017 06:40am EST 

J&J : Johnson & Johnson announces quarterly dividend for first quarter 2017 .Sets quarterly cash dividend of $0.80per share.  Full Article

Ionis Pharmaceuticals says earned $5 mln milestone payment from Janssen Biotech
Thursday, 22 Dec 2016 07:00am EST 

Ionis Pharmaceuticals Inc : Ionis Pharmaceuticals earns milestone payment from Janssen for advancing a new program under GI collaboration . Ionis Pharmaceuticals - earned $5 million milestone payment from Janssen Biotech associated with validation of undisclosed target to treat patients with gastrointestinal autoimmune disease . Ionis Pharmaceuticals - under collaboration, Ionis,Janssen will continue to evaluate target with goal of advancing an antisense drug into development . Ionis Pharma -under terms of agreement, co is eligible to receive nearly $800 million in development, regulatory, sales milestone payments, license fees .Ionis Pharmaceuticals Inc - will receive tiered royalties that on average are double-digits on sales from any product that is commercialized.  Full Article

Janssen submits two applications to FDA seeking approval of Simponi Aria
Tuesday, 20 Dec 2016 04:45pm EST 

Johnson & Johnson : Janssen biotech - data from two separate phase 3 studies evaluating efficacy and safety of simponi aria 2 served as basis for submissions .Janssen submits two applications to fda seeking approval of simponi aria® (golimumab) for the treatment of active psoriatic arthritis and active ankylosing spondylitis.  Full Article

Actelion says in discussions with another party regarding possible strategic transaction
Tuesday, 13 Dec 2016 08:11pm EST 

Actelion Ltd : Actelion - Actelion is engaged in discussions with another party regarding a possible strategic transaction . Actelion update on strategic transaction discussions . Actelion - Confirms that J&J has withdrawn from the discussions .Actelion - There can be no certainty at this point that any transaction will result.  Full Article

Actelion has given J&J access to some of its financial information as part of the deal negotiations - Bloomberg, citing sources
Tuesday, 29 Nov 2016 11:05am EST 

: Actelion has given J&J access to some of its financial information as part of the deal negotiations - Bloomberg, citing sources .One option being discussed is creating separate entity for Actelion's experimental drugs & research activities - Bloomberg, citing sources.  Full Article

J&J said to make takeover approach for Swiss drugmaker Actelion - Bloomberg
Thursday, 24 Nov 2016 01:55pm EST 

:J&J said to make takeover approach for Swiss drugmaker Actelion - Bloomberg, citing sources.  Full Article

MDL Watch: Sanofi Taxotere, Bair Hugger and J&J talc cases grow

New multidistrict litigation over claims that a Sanofi breast cancer drug causes permanent hair loss more than doubled in size over the past month, and plaintiffs are continuing to mount ovarian cancer claims involving Johnson & Johnson's talc products in federal court.